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Background. Determining cervical precancer risk among human immunodeficiency virus (HIV)–infected
women who despite a normal Pap test are positive for oncogenic human papillomavirus (oncHPV) types is impor-
tant for setting screening practices.
Methods. A total of 2791 HIV-infected and 975 HIV-uninfected women in the Women’s Interagency HIV
Study were followed semiannually with Pap tests and colposcopy. Cumulative risks of cervical intraepithelial neo-
plasia grade 2 or greater (CIN-2+; threshold used for CIN treatment) and grade 3 or greater (CIN-3+; threshold to set
screening practices) were measured in HIV-infected and HIV-uninfected women with normal Pap tests, stratified by
baseline HPV results, and also in HIV-infected women with a low-grade squamous intraepithelial lesion (LSIL;
benchmark indication for colposcopy).
Results. At baseline, 1021 HIV-infected and 518 HIV-uninfected women had normal Pap tests, of whom 154
(15%) and 27 (5%), respectively, tested oncHPV positive. The 5-year CIN-2+ cumulative risk in the HIV-infected
oncHPV-positive women was 22% (95% confidence interval [CI], 9%–34%), 12% (95% CI, 0%–22%), and 14% (95%
CI, 2%–25%) among those with CD4 counts <350, 350–499, and ≥500 cells/µL, respectively, whereas it was 10%
(95% CI, 0%–21%) in those without HIV. For CIN-3+, the cumulative risk averaged 4% (95% CI, 1%–8%)
in HIV-infected oncHPV-positive women, and 10% (95% CI, 0%–23%) among those positive for HPV type 16.
In HIV-infected women with LSIL, CIN-3+ risk was 7% (95% CI, 3%–11%). In multivariate analysis, HIV-infected
HPV16-positive women had 13-fold (P = .001) greater CIN-3+ risk than oncHPV-negative women (referent), and
HIV-infected women with LSIL had 9-fold (P < .0001) greater risk.
Conclusions. HIV-infected women with a normal Pap result who test HPV16 positive have high precancer risk
(similar to those with LSIL), possibly warranting immediate colposcopy. Repeat screening in 1 year may be appro-
priate if non-16 oncHPV is detected.
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Clinical guidelines for cervical cancer screening in the
general population have undergone significant changes
in the past several years. In particular, testing for onco-
genic human papillomavirus (oncHPV), the central
etiologic agent in most cervical tumors, has been in-
creasingly incorporated into routine screening practic-
es. Current US guidelines endorse concurrent Pap and
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oncHPV testing (“co-testing”) for women aged 30 years and
older [1], with repeat screening recommended in 5 years if both
tests are negative. These guidelines reflect the strong 5-year neg-
ative predictive value of a negative co-test in screening for cervical
cancer and precancer [2]. Conversely, if the Pap result is normal
but the oncHPV test is positive, then screening is to be repeated in
12 months, and if genotyping specifically detects either HPV type
16 or 18 (which account for approximately 50% and 10% of
cervical cancers, respectively), immediate colposcopy is recom-
mended [1]. In April 2014, the US Food and Drug Administra-
tion additionally approved an oncHPV assay for use as an
alternative to the Pap test in primary screening among women
in the general population aged ≥25 years [3, 4].
Women with human immunodeficiency virus (HIV) infec-
tion are at several-fold greater risk of cervical cancer than
those in the general population [5–7], as well as several-fold
greater risk of high-grade cervical intraepithelial neoplasia
(CIN-2+ and CIN-3+) [8, 9]. Nonetheless, a recent study in
the Women’s Interagency HIV Study (WIHS), a large prospec-
tive cohort of HIV-infected and HIV-uninfected women, re-
ported that HIV-infected women with normal Pap tests who
additionally co-tested negative for oncHPV have a similar low
5-year risk of CIN-2+ and CIN-3+ as those who are HIV unin-
fected [10].Under the principle of “equal management for equal
risk,” agreed to at a 2012 US consensus conference [11–13],
these data suggested that similar screening practices could be
used to co-test negative women regardless of HIV status.
However, that prior WIHS study did not examine CIN-2+
and CIN-3+ risk among the subset of HIV-infected women
with normal Pap tests who co-tested positive (not negative)
for oncHPV. In addition, data in HIV-infected women are
needed to more specifically assess risk in those with HPV16
or HPV18 despite a normal Pap, and it is important to concom-
itantly study HIV-infected women with low-grade squamous
intraepithelial lesions (LSILs) by Pap test. The 2012 consensus
conference suggested that LSIL be considered a benchmark in-
dication for immediate colposcopy, and the similarity in CIN-
3+ risk (ie, >5%) between women with LSIL and women with a
normal Pap who were positive for HPV16 or HPV18 was a
major reason that detection of either HPV type was named
an additional indication for immediate colposcopy in the
general population [12].
To have adequate data to address these issues, the current
study used results from 2 WIHS enrollment cohorts, including
women recruited during 1994–1995, and those recruited dur-
ing 2001–2002 (who were participants in the WIHS study
mentioned above). We then contrasted the risks of CIN-2+
and CIN-3+ in HIV-infected women with a normal Pap
who tested positive for oncHPV (particularly HPV16 and




The WIHS is an ongoing prospective study of HIV-infected and
at-risk HIV-uninfected women enrolled through similar sourc-
es at 6 sites (Bronx and Brooklyn, New York; Chicago, Illinois;
Los Angeles and San Francisco, California; Washington, Dis-
trict of Columbia). Enrollment was initially conducted between
October 1994 and November 1995 (n = 2054 HIV infected,
n = 569 HIV uninfected), and a second cohort was similarly en-
rolled between October 2001 and September 2002 (n = 737 HIV
infected, n = 406 HIV uninfected). Details of the WIHS data
collection and recruitment methods have been reported [15].
In brief, participants undergo a semiannual visit that involves
a gynecologic examination with specimen collection, including
a Pap test and cervicovaginal lavage for HPV DNA testing. All
cervical cytology was centrally interpreted using the 1991 or
2001 Bethesda System criteria for cytologic diagnosis [16, 17].
Colposcopy was recommended for all Pap results of atypical
squamous cells of undetermined significance or worse (ASC-
US+). Written informed consent was obtained from all partic-
ipants, and the study was approved by each local institutional
review board.
Laboratory Testing
HPV DNA detection methods have been described in detail
elsewhere [8, 18]. In brief, HPV DNA was detected using
a well-established degenerate primer MY09/MY11/HMBO1
polymerase chain reaction (PCR) assay. Primer set PC04/
GH20, which amplifies a cellular β-globin DNA fragment, was
used as an internal control to assess the adequacy of amplifica-
tion. The amplification products were then probed for the pres-
ence of “any HPV” DNA with a generic probe mixture, and
probed for individual HPV types using filters hybridized with
type-specific biotinylated oligonucleotides for >40 individual
HPV DNA types. β-globin–negative specimens were excluded.
Consistent with recommendations from the International Agen-
cy for Research on Cancer, HPV types 16, 18, 31, 33, 35, 39, 45,
51, 52, 56, 58, 59, and 68 were considered oncogenic, and all
other types were considered nononcogenic [19, 20].
Statistical Methods
The analysis included HIV-infected and HIV-uninfected
women who had a normal Pap result or LSIL at their baseline
WIHS enrollment visit (during either 1994–1995 or 2001–
2002). Descriptive statistics were used to examine the baseline
characteristics of these participants, stratified by HIV status,
and compared using the t test (to assess means), Wilcoxon
test (for medians), or Pearson χ2 test (for proportions). Stan-
dard life-table methods were used to estimate the cumulative
risk of CIN-2+ and CIN-3+, with 95% confidence intervals
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(CIs) calculated based on the life-table estimator under a nor-
mal approximation assumption. Participants who had a hyster-
ectomy or who reported having had treatment for CIN were
censored at the visit before the procedure. The log-rank test
was used to compare the cumulative risk of CIN-2+ and CIN-
3+ in HIV-infected women with a CD4 count <350, 350–499,
or ≥500 cells/μL, as well as HIV-uninfected women, according
to their HPV DNA results at baseline. HIV-infected women
with LSIL were studied similarly.
Multivariable Cox models were conducted to study the asso-
ciations of CIN-2+ and CIN-3+ with detection of any oncHPV,
HPV16, HPV18, and non-16/18 oncHPV at baseline, after ad-
justing for other established cervical risk factors. These covari-
ates were a priori parameterized as in prior WIHS studies [9, 10,
21], except for age, which was treated as a continuous variable to
preserve degrees of freedom. Cox models of women with LSIL at
baseline included prevalent cases of CIN-2+ and CIN-3+, as
WIHS participants with LSIL were by protocol referred for im-
mediate colposcopy; that is, baseline CIN-2+ or CIN-3+ is an
important component of the overall cumulative cervical pre-
cancer risk in women with LSIL in this study [22, 23]. The low-
est detectable HIV RNA level changed over calendar time as the
assay sensitivity improved. To simplify modeling, we therefore
used the HIV RNA detection threshold from early in the WIHS,
≤4000 copies/mL, as this could be used as the referent across all
women at all visits [22, 23]. In secondary analysis, we included
nonparametric splines in our Cox models to assess whether
incorporating time-varying effects meaningfully impacted the
results [24, 25]. Statistical significance was defined as P < .05
determined using 2-sided tests.
RESULTS
There were 1727 HIV-infected and 806 HIV-uninfected women
with a normal cervical Pap at enrollment. Women were exclud-
ed from analysis if (1) their baseline HPV or CD4 cell count
data were unavailable (n = 198 HIV-infected and n = 66 HIV-
uninfected women); (2) hysterectomy was performed prior to
enrollment (n = 129 and n = 37); (3) follow-up data were un-
available (n = 115 and n = 71); or (4) HIV seroconversion oc-
curred during follow-up (n = 9). Among the remaining 1285
HIV-infected and 623 HIV-uninfected women, 290 were not
compliant with colposcopy (n = 206 and n = 84), and 79 were
excluded due to self-reported cervical treatment prior to base-
line (n = 58 and n = 21).
Overall, 1021 HIV-infected and 518 HIV-uninfected women
were included in the analysis of CIN-2+ and CIN-3+ cumula-
tive risk. Table 1 shows selected baseline characteristics of these
women. Although HIV-infected women reported less recent sex-
ual activity, they were more likely than HIV-uninfected women
to test positive for any HPV DNA (37% vs 19%; P < .0001).
Table 1. Baseline Characteristics of Human Immunodeficiency
Virus (HIV)-Infected and HIV-Uninfected Women Who Had a Normal





(n = 518) P Valuea
Age, y
Mean (SD) 35 (8) 32 (8) <.0001
Race/ethnicity, No. (%) .59
Black 535 (52) 271 (52)
Hispanic 291 (29) 146 (28)
White 165 (16) 79 (15)




1994–1995 683 (67) 277 (53)
2001–2002 338 (33) 241 (47)
Smoking, No. (%) .001
Never 382 (38) 158 (31)
Former 166 (16) 68 (13)
Current 470 (46) 292 (56)
Sexually active in the last
6 mo, No. (%)
<.0001
Yes 714 (70) 422 (82)
No 300 (30) 95 (18)
Lifetime No. of sexual
partners, No. (%)
.003
<5 261 (26) 97 (19)
5–9 205 (20) 118 (23)
10–49 319 (32) 199 (39)
≥50 219 (22) 100 (19)
HPV DNA test results,
No. (%)
<.0001
Negative 646 (63) 416 (80)
Nononcogenic 221 (22) 75 (14)
Any oncogenic 154 (15) 27 (5)
HPV16b 24 (2) 3 (1)
HPV18b 14 (1) 4 (1)





HIV RNA, copies/mL, No. (%)
≤4000c 442 (44)
4001–20 000 228 (23)
20 001–100 000 214 (21)
>100 000 121 (12)
HAART use in past 6 mo, No. (%)
Yes 161 (16)
No 860 (84)
Abbreviations: HAART, highly active antiretroviral therapy; HIV, human
immunodeficiency virus; HPV, human papillomavirus; SD, standard deviation.
a Based on 2-sided t test (means), Wilcoxon test (medians), or Pearson χ2 test
(proportions) comparing HIV-infected and HIV-uninfected women.
b Two HIV-infected women were positive for both HPV16 and HPV18 at
baseline.
c The lowest detectable HIV RNA level changed over time as assay sensitivity
improved. To simplify modeling, we used the detection threshold from early in
the study (ie, ≤4000 copies/mL) as this could be used as referent for all women
at all visits.
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OncHPV was detected in 154 (15%) HIV-infected and 27 (5%)
HIV-uninfected women (P < .0001) with normal Pap tests. For
HPV16 and HPV18 the prevalence was 2% and 1%, respectively,
among the HIV-infected women, whereas it was 1% each among
the HIV-uninfected women. The women with HIV were older
and less likely than HIV-uninfected women to be current
smokers. Sixty-seven percent of the HIV-infected women had a
CD4 count ≥350 cells/μL, and 16% (ie, half of those recruited
during 2001–2002) reported highly active antiretroviral therapy
(HAART) use at baseline. The length of follow-up averaged
14 person-visits, including a median of 13 person-visits in HIV-
infected women and 14 person-visits in HIV-uninfected women—
a total of 14 415 and 7382 person-visits of data, respectively.
Cumulative Risk of CIN-2+ and CIN-3+
Any Oncogenic HPV
CIN-2+. HIV-infected women who had a normal Pap and
were oncHPV negative (n = 867) had a total of 22 CIN-2+
cases during 5 years of follow-up. More specifically, the cumu-
lative risk was 2% (95% CI, 0%–5%) in HIV-infected women
with a CD4 count <350 cells/µL, 4% (95% CI, 1%–6%) with a
CD4 count of 350–499 cells/µL, 3% (95% CI, 1%–5%) with a
CD4 count ≥500 cells/µL, and 2% (95% CI, 1%–3%) in HIV-
uninfected women (n = 491). Among women with a normal Pap
result who were oncHPV positive (n = 154 HIV-infected and
n = 27 HIV-uninfected), the 5-year cumulative risk of CIN-2+
was 22% (95% CI, 9%–34%) in HIV-infected individuals with
a CD4 count <350 cells/µL, 12% (95% CI, 0%–22%) with a
CD4 count 350–499 cells/µL, and 14% (95% CI, 2%–25%)
with a CD4 count ≥500 cells/µL—an overall cumulative risk
of 16% (95% CI, 9%–23%) among oncHPV-positive, HIV-
infected women (Figure 1A). The CIN-2+ risk was 10% (95%
CI, 0%–21%) in oncHPV-positive, HIV-uninfected women.
CIN-3+. No cases of CIN-3+ occurred in HIV-uninfected
women during 5 years of follow-up. In HIV-infected women
with a normal Pap result who were oncHPV negative, 9 were
CIN-3+ cases, a cumulative risk of ≤1% in each CD4 stratum.
Among the oncHPV-positive women, there was a total of 5
CIN-3+ cases, with a 5-year cumulative risk of 7% (95% CI,
0%–15%) in HIV-infected women with a CD4 count <350
cells/µL, 2% (95% CI, 0%–7%) with a CD4 count 350–499
cells/µL, and 2% (95% CI, 0%–7%) with a CD4 count ≥500
cells/µL—an overall cumulative risk of 4% (95% CI, 0%–8%)
among oncHPV-positive, HIV-infected women (Figure 1B).
HPV16/18 and LSIL. As shown in Figure 1A, HIV-infected
women with a normal Pap result who were HPV16 positive had
a 3-year cumulative risk of CIN-2+ of 29% (95% CI, 6%–46%)
with no additional cases detected between 3–5 years, whereas
those with non-16 oncHPV (not shown) had a 3-year and
5-year cumulative incidence of 9% (95% CI, 3%–14%) and 14%
(95% CI, 7%–21%), respectively. The CIN-3+ cumulative risk
(Figure 1B) in HPV16-positive, HIV-infected women was 10%
(95% CI, 0%–23%) after 3 years, which remained unchanged
(with no additional cases) through 5 years of follow-up, whereas
Figure 1. Cumulative risk of cervical intraepithelial neoplasia grade 2 or greater (CIN-2+; A) and grade 3 or greater (CIN-3+; B), among human immu-
nodeficiency virus-infected women who at baseline had a normal Pap result with no oncogenic human papillomavirus (HPV) (blue diamonds), any oncogenic
HPV (red squares), HPV type 16 (green triangles), or had a baseline Pap diagnosed as low-grade squamous intraepithelial lesion (LSIL) (purple crosses). The
cumulative risk for women with LSIL includes both prevalent and incident cases, as LSIL is an indication for immediate colposcopy, whereas for all other
groups the data reflect cumulative incidence.
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the risk over 5 years in those with non-16 oncHPV was 3% (95%
CI, 0%–6%) (not shown).
No cases of HPV18-positive CIN-2+ or CIN-3+ were detected
in the HIV-infected women studied. However, among HIV-
infected women with LSIL, the 3-year cumulative risk of CIN-
3+ was 7% (95% CI, 3%–11%), with no additional cases detected
between 3 and 5 years of follow-up.
Multivariate Cox Models
Our initial models assessed the associations of oncHPV detec-
tion (yes/no) and host immune status (ie, HIV infection and
CD4 count) with subsequent risk of CIN-2+ and CIN-3+
after 3 years or 5 years of follow-up, controlling for multiple co-
factors. For CIN-2+ (Table 2), the detection of any oncHPV vs
no oncHPV was associated with a 3-year hazard ratio (HR) of
6.4 (95% CI, 3.1–12.9; P < .0001) and a 5-year HR of 5.3 (95%
CI, 2.9–9.4; P < .0001). Although HIV status was associated
with a significant increase in CIN-2+ risk, there was no clear
biologic gradient between CIN-2+ and decreasing CD4 cell
count (Ptrend > .5) in these multivariate analyses. Similar results
were also obtained using CIN-3+ as the endpoint (Table 3). In
additional models (Table 4), we found strong associations of
HPV16 with CIN-3+ risk during 3 years (HR, 18.7 [95% CI,
3.6–96.9]; P < .001) and 5 years (HR, 13.3 [95% CI, 2.7–64.3];
P < .001) of follow-up, as well as between detection of LSIL
and CIN-3+ risk during the same 3-year (HR, 12.2 [95% CI,
4.0–37.0]; P < .0001) and 5-year (HR, 9.4 [95% CI, 3.5–25.6];
P < .0001) periods. These results were unaltered by limiting
analysis to only HIV-infected women, controlling for HIV
RNA level (as parameterized in Table 1) and use of HAART,
and incorporating “number of sex partners in the prior 6
months” instead of “lifetime number of sexual partners” in
Table 2. Risk of Cervical Intraepithelial Neoplasia Grade 2 or Greater (CIN-2+) After 3 or 5 Years of Follow-up, and Its Relationship With
Oncogenic Human Papillomavirus Detection at Baseline in Human Immunodeficiency Virus (HIV)-Infected and HIV-Uninfected Women
With a Normal Baseline Pap Resulta
Characteristic 3 y HR (95% CI) P Value 5 y HR (95% CI) P Value
HPV status
OncHPV negative Reference Reference
OncHPV positive 6.4 (3.1–12.9) <.0001 5.3 (2.9–9.4) <.0001
Year of enrollment
1994–1995 Reference Reference
2001–2002 1.1 (.5–2.3) .8 1.0 (.5–1.8) .9
CD4 count (HIV+)
HIV− Reference Reference
>500 cells/µL 3.2 (1.1–9.4) .04 2.3 (1.0–5.1) .05
350–500 cells/µL 2.2 (.6–7.4) .2 1.8 (.7–4.5) .2
<350 cells/µL 4.9 (1.6–15.4) .01 3.0 (1.3–7.1) .01
Age at baseline (continuous) 0.9 (.9–1.0) .005 0.9 (.9–1.0) .003
Race
Black Reference Reference
Hispanic 1.6 (.7–3.4) .3 1.1 (.6–2.2) .7
White 0.2 (.0–1.6) .1 0.3 (.1–1.0) .1
Other 2.3 (.6–8.2) .2 2.1 (.7–6.1) .2
Smoking
Never Reference Reference
Past 1.7 (.6–4.4) .3 1.2 (.5–3.0) .7
Current 1.1 (.5–2.5) .8 1.5 (.8–2.9) .2
Lifetime No. of male sexual partners
<5 Reference Reference
5–9 1.5 (.5–4.4) .4 1.2 (.5–2.8) .7
10–49 2.0 (.7–5.4) .2 1.6 (.7–3.6) .2
≥50 1.4 (.4–4.6) .6 0.9 (.3–2.3) .8
Abbreviations: CI, confidence interval; HIV, human immunodeficiency virus; HPV, human papillomavirus; HR, hazard ratio; OncHPV; oncogenic human
papillomavirus.
a In secondary data analysis, we observed similar results when incorporating nonparametric splines in the Cox model; that is, the average HRs after 3 or 5 years of
follow-up, as measured using the area under the curve, were similar to those presented in the tables, and no statistically significant departures from proportionality
were detected.
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the model; that is, the 5-year relative risk of CIN-3+ related to
HPV16 detection was an HR of 14.5 (95% CI, 2.7–78.7;
P = .001), whereas for LSIL it was an HR of 11.9 (95% CI,
3.8–37.0). Moreover, no statistically significant differences in
CIN-3+ risk were found between HIV-infected women with a
normal Pap who were HPV16 positive vs those who had LSIL
(all P > .50). Additional details regarding eachmodel are reported
in the footnotes to Tables 2–4. Year of enrollment had no relation
with CIN-2+ or CIN-3+ risk in any multivariate models.
DISCUSSION
We determined the cumulative risk of CIN-2+ and CIN-3+
among HIV-infected women who, despite having a normal
baseline Pap, co-tested positive for HPV16 or other oncHPV
types. Whereas prior studies reported that HIV-infected
women with a normal Pap who additionally tested oncHPV
negative had a similar low incidence of CIN-2+ and CIN-3+
as HIV-uninfected individuals [10, 26], the risk of high-grade
cervical lesions (ie, precancer) in HIV-infected women with a
normal Pap result who instead tested oncHPV positive has
not to our knowledge been reported.
The most striking finding was the very high risk of CIN-2+ and
CIN-3+ among HIV-infected women with a normal Pap result
who tested HPV16 positive; that is, a 5-year cumulative incidence
of CIN-2+ of 29% and CIN-3+ of 10%. No HPV18-positive CIN-
2+ and CIN-3+ were detected during the same follow-up period.
In multivariable Cox models, testing positive for HPV16 vs
oncHPV negative at baseline was associated with a 13-fold greater
risk of CIN-3+ among HIV-infected women with a normal Pap
result.
To benchmark these results against an accepted indication
for immediate colposcopy, we concomitantly measured the
risk of CIN-3+ in HIV-infected women with a Pap diagnosis
of LSIL [12, 13]. In both Kaplan–Meier and multivariate Cox
models, HIV-infected women with a normal Pap result who
tested positive for HPV16 had nonsignificantly higher risk of
CIN-3+ than did HIV-infected women with LSIL. Based on
the principle of “equal management of equal risks,” the fol-
low-up in both groups should be similar because they have sim-
ilar risk of CIN-3+ [12, 13]. If correct, the collective data
therefore suggest that immediate colposcopy might be appro-
priate in HIV-infected women who test HPV16 positive despite
a normal Pap result, as in HIV-infected women with LSIL.
Table 3. Risk of Cervical Intraepithelial Neoplasia Grade 3 or Greater (CIN-3+) After 3 or 5 Years of Follow-up, and Its Relationship With
Oncogenic Human Papillomavirus Detection at Baseline in Human Immunodeficiency Virus (HIV)-Infected and HIV-Uninfected Women
With a Normal Baseline Pap Resulta
Characteristic 3 y HR (95% CI) P Value 5 y HR (95% CI) P Value
HPV status
OncHPV negative Reference Reference
OncHPV positive 5.3 (1.6–18.3) .01 4.1 (1.3–12.8) .02
CD4 count (HIV+)
HIV− Reference Reference
>500 cells/µL 1.3 (.2–9.4) .8 1.0 (.2–4.5) 1.0
350–500 cells/µL 2.7 (.4–17.1) .3 1.4 (.3–6.4) .7
<350 cells/µL 3.7 (.6–23.1) .2 1.8 (.4–7.8) .5
Age at baseline (continuous) 0.9 (.9–1.0) .1 1.0 (.9–1.0) .2
Smoking
Never Reference Reference
Past 1.5 (.3–8.3) .7 1.4 (.2–7.7) .7
Current 1.1 (.3–4.2) .9 1.7 (.5–5.8) .4
Lifetime No. of male sexual partners
<5 Reference Reference
5–9 1.1 (.2–5.4) 1.0 1.3 (.3–6.0) .7
≥10 1.0 (.2–4.1) 1.0 1.1 (.3–4.4) 1.0
Abbreviations: CI, confidence interval; CIN, cervical intraepithelial neoplasia; HIV, human immunodeficiency virus; HPV, human papillomavirus; HR, hazard ratio;
OncHPV; oncogenic human papillomavirus.
a The number of covariates were a priori reduced from the model shown in Table 2 to decrease the degrees of freedom used in this model, given the smaller number
of CIN-3+ than CIN-2+ events. In secondary data analysis, we observed similar results when incorporating nonparametric splines in the Cox model; that is, the
average HRs after 3 or 5 years of follow-up, as measured using the area under the curve, were similar to those presented in the tables, and no statistically
significant departures from proportionality were detected.
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Furthermore, current US guidelines recommend follow-up
screening in 1 year for women in the general population who
are oncHPV positive but lack additional HPV genotype data,
or who test positive only for oncHPV types other than
HPV16 or HPV18 [1, 14]. Consistent with this, our data showed
that although the risk of CIN-2+ and CIN-3+ was elevated in
HIV-infected women with a normal Pap and any oncHPV
(or non-16 oncHPV types), relative to those who tested
oncHPV-negative, this risk was lower than in those with LSIL.
Thus, the current findings suggest that repeat screening in
1 year might be appropriate in HIV-infected women with a nor-
mal Pap and non-16 oncHPV types or who lack type-specific
results.
The current findings are also interesting for another reason:
They provide new information regarding the special character
of HPV16, the most carcinogenic HPV type. Our group and
others have previously shown that the prevalence of HPV16 is
the least affected of any oncHPV type by changes in host
immune status among HIV-infected women (as measured by
CD4 cell count) [27–29]. This relative independence of
HPV16 infection from host immune status has been interpreted
as evidence that HPV16 may have a greater innate ability to
avoid the effects of immune surveillance than other oncHPV
types. Consistent with this, we have recently reported that
HPV16 is present in a significantly lower percentage of
CIN-3+ in HIV-infected (25%) than in HIV-uninfected
(>60%) women in the WIHS cohort (L. S. Massad et al, submit-
ted). Taken together, the current study and prior data collective-
ly suggest that although the prevalence of HPV16 may be less
affected by low CD4 cell count than other oncHPV types,
Table 4. Multivariate Cox Model of Cervical Intraepithelial Neoplasia Grade 3 or Greater (CIN-3+) Risk Among Human Immunodeficiency
Virus (HIV)-Infected and HIV-Uninfected Women With a Normal Pap Result After 3 or 5 Years of Follow-upa, Women’s Interagency HIV Study
Characteristic 3 y HR (95% CI) P Value 5 y HR (95% CI) P Value
HPV and LSIL status
OncHPV negative Reference Reference
Non-16 OncHPV positive 4.2 (1.0–17.6) .05 2.9 (.7–11.3) .13
HPV16 positive 18.7 (3.6–96.9) .001 13.3 (2.7–64.3) <.001
LSIL 12.2 (4.0–37.0) <.0001 9.4 (3.5–25.6) <.0001
Enrollment period
1994–1995 Reference Reference
2001–2002 0.9 (.3–2.5) .83 0.9 (.4–2.3) .81
CD4 count (HIV+)
HIV− Reference Reference
>500 cells/µL 2.6 (.5–13.9) .27 1.7 (.5–6.3) .44
350–500 cells/µL 1.9 (.3–12.2) .50 1.1 (.2–5.1) .95
<350 cells/µL 3.4 (.7–17.7) .15 2.1 (.6–7.5) .28
Age at baseline 0.97 (.9–1.0) .37 0.97 (.9–1.0) .40
Race
Black Reference Reference
Hispanic 1.3 (.5–3.5) .60 1.1 (.5–2.9) .79
White 0.6 (.1–2.7) .48 0.5 (.1–2.3) .38
Other 1.3 (.2–10.3) .82 2.2 (.5–10.2) .31
Smoking
Never Reference Reference
Past 2.3 (.6–9.0) .23 2.3 (.6–8.9) .23
Current 2.6 (.9–7.7) .08 3.0 (1.1–8.5) .04
Lifetime No. of male sexual partners
<5 Reference Reference
5–9 0.5 (.1–2.0) .31 0.6 (.2–2.1) .40
10–49 1.4 (.5–4.1) .51 1.2 (.4–3.5) .69
≥50 0.1 (.0–1.1) .06 0.4 (.1–1.5) .15
Abbreviations: CI, confidence interval; HIV, human immunodeficiency virus; HPV, human papillomavirus; HR, hazard ratio; LSIL, low-grade squamous intraepithelial
lesion; OncHPV; oncogenic human papillomavirus.
a In secondary data analysis, we observed similar results when incorporating nonparametric splines in the Cox model; that is, the average HRs after 3 or 5 years of
follow-up, as measured using the area under the curve, were similar to those presented in the table, and no statistically significant departures from proportionality
were detected.
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when cervical HPV16 infection does occur, it is strongly asso-
ciated with risk of CIN-2+ and CIN-3+ in HIV-infected
women.
Several limitations to this study should be considered in in-
terpreting the findings. The first and most important is that the
cumulative risk estimates for CIN-2+ and CIN-3 had wide CIs,
indicating that statistical power in this study was somewhat lim-
ited. This concern may also explain the failure to detect HPV18
in any CIN-2+ or CIN-3+ cases. Thus, a multicohort analysis to
expand upon the current results may be warranted, as there are
few other similarly large cohorts with appropriate follow-up
and data. It would be beneficial for such an analysis to focus
more extensively on the current HAART era and to more care-
fully address the effects of HAART than was possible in the cur-
rent study. Additionally, the results in WIHS women may not
be generalizable beyond HIV-infected individuals who are like-
wise in long-term care; albeit, this includes a growing fraction of
US women with HIV. Last, the extent to which these data are
applicable to populations outside the United States is uncertain,
particularly those in resource-limited settings.
Overall, the current data suggest that HIV-infected women
may benefit from cervical cancer co-testing using Pap and
oncHPV assays, as is recommended in the general population
[1]. Repeat co-testing at 1 year may be a reasonable approach
in HIV-infected women with a normal Pap who are oncHPV
positive [1]. HPV genotyping may also be appropriate in
HIV-infected women, as the high risk of CIN-2+ and CIN-3+
in individuals with a normal Pap and HPV16 suggests that im-
mediate colposcopy may be appropriate in these individuals.
Were these practices adopted, the current data suggest that
approximately 15% of HIV-infected women with a normal
Pap would be referred to follow-up screening in 1 year and
2% to immediate colposcopy; that is, 15% of women with a nor-
mal Pap were oncHPV positive and 2% were HPV16 positive.
However, HIV-infected women who are unable to obtain
oncHPV testing can also be followed with annual Pap tests,
and for those with 3 serial negative Pap tests, longer intervals
until repeat screening may be appropriate [30]. In future stud-
ies, it will be important to focus more extensively on HIV-
infected women with abnormal Pap tests and to incorporate
additional molecular assays to more accurately identify the
subset of individuals with high risk of cervical precancer and
cancer, either at the time of screening or within a few years of
gynecologic assessment. Cost effectiveness should be carefully
considered prior to implementation of any new cervical cancer
screening guidelines in HIV-infected women.
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